ClinicalTrials.gg
RecruitingNCT07089862Updated Mar 16, 2026

INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT)

An interventional study of Indobufen treatment and Aspirin treatment in Unruptured Intracranial Aneurysm and Indobufen, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,500
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Intracranial Aneurysm by Beijing Tiantan Hospital — 7 open to participants now, 8 under way, 1 of them phase 3. Intracranial Aneurysm · Beijing Tiantan Hospital.

Started
2025
with 1 other
No phase
5 of 20
2 open now
Registered
18th of 20
by date

Among the 20 studies in Intracranial Aneurysm by Beijing Tiantan Hospital, this one is one of 2 that started in 2025, is one of 5 with no phase, and was the 18th registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

7 of the 20 studies in Intracranial Aneurysm by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Intracranial Aneurysm by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

This project aims to evaluate the safety and efficacy of the antiplatelet regimen combining indobufen and clopidogrel in preventing ischemic events after stent-assisted coiling embolization and flow diverter implantation for intracranial aneurysms.

Using a randomization system, patients with unruptured intracranial aneurysms scheduled for interventional treatment will be divided into an experimental group and a control group. Patients in the experimental group will be required to take indobufen (100 mg twice daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively. Patients in the control group will be required to take aspirin (100 mg once daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively.

An independent group of researchers will assess cerebrovascular thromboembolic events and bleeding events at different time points.

03

Conditions studied

  • Unruptured Intracranial Aneurysm
  • Indobufen

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years (male or female);
  2. Radiologically confirmed saccular intracranial aneurysm (by specialist assessment);
  3. Scheduled for endovascular embolization (including: coil embolization with stent assistance or flow diversion);
  4. Signed obtained.

Exclusion criteria

Exclusion Criteria:

  1. Concomitant vascular malformations, tumors, abscesses or other cerebral diseases such as multiple sclerosis;
  2. Major surgery within 30 days prior to enrollment including fracture surgery or hip replacement;
  3. History of ischemic stroke, ischemic heart disease or hemorrhagic disorders including intracranial hemorrhage, gastrointestinal bleeding, fundus hemorrhage or unexplained bleeding within the past 6 months;
  4. Planned elective surgery within 3 months after the procedure;
  5. Any hematologic disorders or inherited coagulation abnormalities;
  6. Severe renal or hepatic dysfunction;
  7. History of hemostatic disorders, systemic bleeding, thrombocytopenia or neutropenia;
  8. History of symptomatic non-traumatic intracranial hemorrhage or cerebral amyloid angiopathy;
  9. Severe cardiopulmonary diseases considered by investigators to be unsuitable for the study;
  10. Women of with negative pregnancy test but refusing measures, or those who are pregnant or lactating;
  11. Current participation in other drug or device trials.

Withdrawal Criteria:

  1. Receiving aneurysm treatment other than coil embolization with stent assistance or flow diversion;
  2. Occurrence of endpoint events during stent-assisted aneurysm embolization procedure (as adjudicated by the Clinical Events Committee), including procedure-related hemorrhagic events (aneurysm rupture, parent artery rupture, subarachnoid hemorrhage, acute ipsilateral intracerebral hemorrhage, and acute ipsilateral subdural/epidural hematoma) or ischemic events (acute large vessel occlusion, in-stent thrombosis, and diffuse ipsilateral vascular infarction caused by plaque dislodgement);
  3. Device-related quality issues during stent-assisted embolization, including stent problems (stent fracture, failure to deploy properly, incomplete expansion due to product defect) and coil problems (premature detachment before intentional deployment, coil unraveling, and failure to detach);
  4. Postoperative \<3 months;
  5. Inability to complete 5-day premedication due to emergency surgery or other reasons;
  6. Intolerance to oral antiplatelet therapy due to allergy or other .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,500 participants (estimated)

Study arms

  • Experimental
    Indobufen+clopidogrel group

    Patients in the experimental group will be required to take indobufen (100 mg twice daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively.

    Drug: Indobufen treatment

  • Active comparator
    Aspirin+clopidogrel group

    Patients in the control group will be required to take aspirin (100 mg once daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively.

    Drug: Aspirin treatment

Interventions

  • DrugIndobufen treatment

    Patients in the experimental group will be required to take indobufen (100 mg twice daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively.

  • DrugAspirin treatment

    Patients in the control group will be required to take aspirin (100 mg once daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively.

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Endpoint Events: Cerebrovascular thromboembolic events occurring within 90 days postoperatively

    Cerebrovascular thromboembolic events within 90 days after endovascular treatment of unruptured intracranial aneurysms, including: Ischemic stroke, Transient ischemic attack (TIA), Stent thrombosis, Emergency revascularization, Cerebrovascular death

    Time frame: within 90 days after endovascular treatment of unruptured intracranial aneurysms

  2. Primary Safety Endpoint Events: Incidence of bleeding events classified as Type 2, 3, or 5 according to the Bleeding Academic Research Consortium (BARC) criteria within 90 days after endovascular treatment of unruptured intracranial aneurysms.

    Bleeding events classified as Type 2, 3, or 5 according to the Bleeding Academic Research Consortium (BARC) criteria within 90 days after endovascular treatment of unruptured intracranial aneurysms.

    Time frame: Within 90 days after endovascular treatment of unruptured intracranial aneurysms.

Secondary outcomes

  1. Cerebrovascular thromboembolic events occurring within 30 days postoperatively

    Cerebrovascular thromboembolic events within 30 days after endovascular treatment of unruptured intracranial aneurysms, including: Ischemic stroke, Transient ischemic attack (TIA), Stent thrombosis, Emergency revascularization, Cerebrovascular death

    Time frame: Within 30 days postoperatively

  2. Cerebrovascular thromboembolic events occurring within 180 days postoperatively

    Cerebrovascular thromboembolic events within 180 days after endovascular treatment of unruptured intracranial aneurysms, including: Ischemic stroke, Transient ischemic attack (TIA), Stent thrombosis, Emergency revascularization, Cerebrovascular death

    Time frame: Within 180 days postoperatively

  3. Platelet aggregation rate within 24 hours before surgery

    Platelet aggregation rate within 24 hours before surgery, including ADP-induced platelet aggregation, Collagen-induced platelet aggregation and Arachidonic acid-induced platelet aggregation.

    Time frame: Within 24 hours before surgery

07

Study locations

1 of 1 sites recruiting
  • Capital Medical University Affiliated Beijing Tiantan Hospital
    Beijing, Beijing Municipality, China
    Recruiting
    • Qingyuan Liu, M.D. · Contact13260457220@163.com · +86-13260457220
    • Shuo Wang, M.D. · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

Of 59 non-industry interventional studies with no phase under Intracranial Aneurysm, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 134. This study's planned 16 months is below that.

Counting every sponsor, half of 106 studies reached it within 39 months; a quarter within 22 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Jul 28, 2025
StartActual
Aug 31, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07089862
Collaborators
RenJi Hospital, First Affiliated Hospital of Fujian Medical University, Jiangnan University Central Hospital, Beijing Chao Yang Hospital, Beijing Friendship Hospital, Beijing Shuyi Hospital, The Central Hospital of Lishui City
Responsible party
Wang Shuo (Director of Department of Cerebrovascular Neurosurgery, Beijing Tiantan Hospital) — Principal investigator
First posted
Jul 28, 2025
Start date
Aug 31, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 16, 2026

Study contacts

Qingyuan Liu, M.D.
Contact
13260457220@163.com
+86-13260457220

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion